Vical Incorporated (NASDAQ:VICL)’s Allovectin may be melanoma answer

Posted by Michael Korte June 4, 2013 0 Comment 1850 views


Vical Incorporated (NASDAQ:VICL), is a small-cap biopharma company that seeks to conquer cancer with a pipeline of cancer drugs. Its drug Allovectin is currently in phase III testing for Melanoma, a skin cancer. It has been indicated that Allovectin can treat stage III, and stage IV Melanoma and may be the first line treatment for patients suffering from melanoma. The company feels that Allovectin has the capacity to be more effective than first line treatments that are currently in the market.

VICL trades at a $297.38 million market cap, and the results are slated to come out in late 2013. VICL currently trades at $3.44 per share, which is below its 52-week high of $4.74. Like most other small-cap Biopharma stocks, Vical Incorporated (NASDAQ:VICL) too is a risk. If things go right for VICL, its investors will definitely be able to rake in the profits. By 2015, the Melanoma cancer market is estimated to touch $1.15 billion.

The cancer story

Way back since the 1950s, treating cancer with the use of vaccines has been an extremely challenging investigation-filed. Over the decades, insufficiency of effective immunotherapies led to the demand for novel strategies. In the 21st century, use of therapeutic cancer fighting vaccines has become imperative and the need of the day. In men, lung, prostate, and colorectal cancers are the most common while among women, breast, colorectal and lung cancers are the common forms.

In totality, 49 percent of cancer related deaths in the United States are attributed to lung, prostate, breast and colorectal cancers. And so, many vaccine companies have been experimenting with the development of game-changing technologies to target various types of cancer.

The competitors

Another company that is in Phase III cancer study is Galena Biopharma Inc (NASDAQ:GALE). It too is a small-cap bio-pharma company. It has several kinds of vaccine-candidates in its pipeline, and its product candidate, NeuVax, is in a phase III study for the treatment of breast cancer. It has a market cap of $191.06M. Also, for a company that has a product in a Phase III clinical study, its stock is still being traded pretty cheaply. At last trading close its share price was $2.30 per share, No doubt that Galena is sitting on a goldmine if its vaccine gains approval and if it manages to make the home run, its investors will be in for a big one.


About Michael Korte

Michael Korte an investigative reporter at GDP Insider and is a breaking news reporter. Michael work includes investigations of misconduct by federal prosecutors and industrial air pollution around the nation's schools. His reporting has been recognized with the Hillman Prize for Newspaper Journalism, the Grantham Prize for Excellence in Reporting on the Environment, and the Philip Meyer Journalism Award for reporting that incorporates social science methods.

View all post by Michael Korte Visit author's website

Write Your Comment